Navigation Links
Drug a New Weapon Against One Form of Breast Cancer
Date:10/10/2007

Adding paclitaxel to standard chemo targets HER2-positive tumors

WEDNESDAY, Oct. 10 (HealthDay News) -- When added to a standard chemotherapy, the drug paclitaxel (Taxol) cuts the recurrence of breast cancer by 41 percent in women with a particular form of tumor, a new study finds.

Those tumors are called "HER2-positive" because their cells produce an excess of the protein human epidermal growth factor receptor-2 (HER2).

In recent years, cancer specialists have found that breast tumors with different characteristics respond differently to various regimens. The new study adds another piece to that puzzle, experts say.

"Over the last 10 years, we have come to realize that breast cancer isn't one disease but a family of diseases," explained study co-author Dr. Eric Winer, director of the breast oncology center at the Dana-Farber Cancer Institute in Boston. "In this study, what we saw is very different benefits for paclitaxel in different subgroups of women," he said.

"This adds to a growing body of literature" about which chemotherapy regimens benefit which types of tumors, added the study's lead author, Dr. Daniel F. Hayes, clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center and professor of internal medicine at the University of Michigan, Ann Arbor.

"We can use the biology of the cancer to select the [appropriate] chemotherapy," he said.

The findings are published in the Oct. 11 issue of the New England Journal of Medicine

The researchers randomly selected 1,500 women from 3,121 patients with lymph node-positive breast cancer, meaning it had spread to nearby lymph nodes; all were part of the Cancer and Leukemia Group B study, a national clinical research effort sponsored by the U.S. National Cancer Institute.

The women had been randomly assigned to get the standard anti-cancer drugs doxorubicin plus cyclophosphamide, followed by either four cycles of the drug paclitaxel or observation only.

The researchers than analyzed tissue samples supplied by the women, looking for the expression of HER2 as well as the tumor's estrogen receptor status.

"Most guidelines say, if a tumor is node-positive, chemo is recommended," Hayes said.

In this study, they found that paclitaxel helped those women whose tumors are HER2-positive, regardless of whether they were estrogen-receptor positive or negative. In contrast, patients whose cancers were HER2-negative and estrogen-receptor positive did not benefit in this study from paclitaxel.

Over the follow up of about 10 years, adding paclitaxel for the treatment of HER2-positive tumors reduced the risk of recurrence by 41 percent.

About 60 percent of women with breast cancer will have HER2-negative and estrogen-receptor positive tumors, noted Winer, who is chief scientific adviser for Susan G. Komen for the Cure, a nonprofit advocacy group.

Hayes did offer one strong caveat: "We want to be cautious about this data," he said, adding that the findings need to be confirmed in other studies.

Winer cautioned that the study, "doesn't tell us what we should do when we approach the patient in clinic tomorrow. We don't want people to say no to chemo based on these results only."

In an editorial accompanying the study, Dr. Anne Moore from Weill Cornell Medical College, New York City, concluded that "the days of 'one size fits all' therapy for patients with breast cancer are coming to an end.''

More information

For more on breast cancer treatment, head to the American Cancer Society.



SOURCES: Daniel F. Hayes, M.D., clinical director, breast oncology program, University of Michigan Comprehensive Cancer Center, and professor, internal medicine, University of Michigan, Ann Arbor; Eric Winer, M.D., director, breast oncology center, Dana-Farber Cancer Institute, Boston, and chief scientific adviser for Susan G. Komen for the Cure


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Smallpox as Biological Weapons?
2. Mouthwash as a weapon
3. New Weapon Against Germs
4. Turmeric and Onions-Weapons against Colon Cancer
5. Researchers Find Secret Weapon Used by SARS Virus
6. A New Weapon Against Obesity
7. Latest Weapon in Battle against Drug-Resistant Bacteria
8. Curcumin –New Weapon Against Colorectal Cance
9. NRI Scientists find Potential Colon Cancer Weapon
10. Battle against Gum Disease Acquires new Weapon
11. Cellular Pathway Yields Potential New Weapon in Vaccine Arsenal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... Women's ... of National Wear Red Day. National Wear Red Day is the first Friday ... women. Heart disease and stroke cause 1 in 3 deaths among women each year ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: ... color grades to their footage. A LUT is a Lookup Table that contains a ... corresponding color indicated by the table. By manipulating each pixel, LUT's can change each ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... of the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider ... Improvements in design and manufacturing not only reduce the weight of the unit, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
Breaking Medicine Technology: